The present study demonstrates the superior therapeutic efficacy of the combinatory treatment with RAD001 and [177Lu]Lu-PP-F11N over monotherapy without severe adverse effects in a preclinical mouse model of CCKBR-positive cancer. This evidence concerns the gene CCKBR and cancer.